File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Toxicity of docetaxel plus cyclophosphamide as adjuvant therapy for breast cancer in Chinese patients - The Hong Kong experience

TitleToxicity of docetaxel plus cyclophosphamide as adjuvant therapy for breast cancer in Chinese patients - The Hong Kong experience
Authors
KeywordsBreast cancer
Chemotherapy
Chinese
Docetaxel
Hong Kong
Issue Date2009
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/AJCO
Citation
Asia-Pacific Journal Of Clinical Oncology, 2009, v. 5 n. 2, p. 123-128 How to Cite?
AbstractAims: The docetaxel and cyclophosphamide (TC) regimen is increasingly popular as adjuvant chemotherapy for operable breast cancers. We conducted a retrospective study in Hong Kong to evaluate the toxicity of this regimen in Chinese patients. Methods: Between January 2007 and May 2008 76 female Chinese patients with resected stage I-III operated invasive breast cancer were treated with 4 cycles of TC (75 and 600 mg/m2, respectively, administered i.v. every 3 weeks for four cycles) in two public regional cancer centers of Hong Kong. A total of 24 (32%) patients also received primary prophylactic ciprofloxacin (500 mg twice daily, day 5-14). Chemotherapy-related toxicities were graded by the CTCAE version 3.0. Results: The median age was 50 (range 26-67). A total of 68 (89%) patients successfully completed four cycles of chemotherapy. 72 (95%) and 16 (21%) patients developed grade 3-4 neutropenia and febrile neutropenia (FN) infection, respectively, in one or more cycles. However, no grade 3-4 anemia or thrombocytopenia events were observed. Other grade 3-4 non-hematological toxicities were also uncommon, apart from allergic reactions in two (3%) patients. No viral reactivation was observed among the 8 hepatitis B carriers. Patients with prophylactic ciprofloxacin had less grade 3-4 FN infection (13% vs 25%, P = 0.214) and a higher chance of receiving the full scheduled dose (88% vs 62%, P = 0.045) than patients without. Conclusion: The myelotoxicity of TC was substantially higher in Chinese patients compared with non-Chinese patients in developed countries. Routine prophylactic measures are recommended to maintain the dose levels and reduce the risk of FN. © Journal compilation © 2009 Blackwell Publishing Asia Pty Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/134643
ISSN
2015 Impact Factor: 1.722
2015 SCImago Journal Rankings: 0.554
ISI Accession Number ID
Funding AgencyGrant Number
Hong Kong Cancer Fund
Funding Information:

This study is supported in part by grants from the Hong Kong Cancer Fund.

References

 

DC FieldValueLanguage
dc.contributor.authorYau, TKen_HK
dc.contributor.authorNg, TYen_HK
dc.contributor.authorSoong, ISen_HK
dc.contributor.authorChoi, CWen_HK
dc.contributor.authorLam, kOen_HK
dc.contributor.authorNg, AWYen_HK
dc.contributor.authorLee, AWMen_HK
dc.contributor.authorTung, Yen_HK
dc.date.accessioned2011-07-05T08:22:44Z-
dc.date.available2011-07-05T08:22:44Z-
dc.date.issued2009en_HK
dc.identifier.citationAsia-Pacific Journal Of Clinical Oncology, 2009, v. 5 n. 2, p. 123-128en_HK
dc.identifier.issn1743-7555en_HK
dc.identifier.urihttp://hdl.handle.net/10722/134643-
dc.description.abstractAims: The docetaxel and cyclophosphamide (TC) regimen is increasingly popular as adjuvant chemotherapy for operable breast cancers. We conducted a retrospective study in Hong Kong to evaluate the toxicity of this regimen in Chinese patients. Methods: Between January 2007 and May 2008 76 female Chinese patients with resected stage I-III operated invasive breast cancer were treated with 4 cycles of TC (75 and 600 mg/m2, respectively, administered i.v. every 3 weeks for four cycles) in two public regional cancer centers of Hong Kong. A total of 24 (32%) patients also received primary prophylactic ciprofloxacin (500 mg twice daily, day 5-14). Chemotherapy-related toxicities were graded by the CTCAE version 3.0. Results: The median age was 50 (range 26-67). A total of 68 (89%) patients successfully completed four cycles of chemotherapy. 72 (95%) and 16 (21%) patients developed grade 3-4 neutropenia and febrile neutropenia (FN) infection, respectively, in one or more cycles. However, no grade 3-4 anemia or thrombocytopenia events were observed. Other grade 3-4 non-hematological toxicities were also uncommon, apart from allergic reactions in two (3%) patients. No viral reactivation was observed among the 8 hepatitis B carriers. Patients with prophylactic ciprofloxacin had less grade 3-4 FN infection (13% vs 25%, P = 0.214) and a higher chance of receiving the full scheduled dose (88% vs 62%, P = 0.045) than patients without. Conclusion: The myelotoxicity of TC was substantially higher in Chinese patients compared with non-Chinese patients in developed countries. Routine prophylactic measures are recommended to maintain the dose levels and reduce the risk of FN. © Journal compilation © 2009 Blackwell Publishing Asia Pty Ltd.en_HK
dc.languageengen_US
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/AJCOen_HK
dc.relation.ispartofAsia-Pacific Journal of Clinical Oncologyen_HK
dc.subjectBreast canceren_HK
dc.subjectChemotherapyen_HK
dc.subjectChineseen_HK
dc.subjectDocetaxelen_HK
dc.subjectHong Kongen_HK
dc.titleToxicity of docetaxel plus cyclophosphamide as adjuvant therapy for breast cancer in Chinese patients - The Hong Kong experienceen_HK
dc.typeArticleen_HK
dc.identifier.emailLam, kO:lamkaon@hku.hken_HK
dc.identifier.authorityLam, kO=rp01501en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1111/j.1743-7563.2009.01204.xen_HK
dc.identifier.scopuseid_2-s2.0-66949148328en_HK
dc.identifier.hkuros266179-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-66949148328&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume5en_HK
dc.identifier.issue2en_HK
dc.identifier.spage123en_HK
dc.identifier.epage128en_HK
dc.identifier.eissn1743-7563-
dc.identifier.isiWOS:000266419200008-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridYau, TK=7006540678en_HK
dc.identifier.scopusauthoridNg, TY=7402229653en_HK
dc.identifier.scopusauthoridSoong, IS=9239786900en_HK
dc.identifier.scopusauthoridChoi, CW=35209788100en_HK
dc.identifier.scopusauthoridLam, kO=35210601000en_HK
dc.identifier.scopusauthoridNg, AWY=16309934800en_HK
dc.identifier.scopusauthoridLee, AWM=17035384900en_HK
dc.identifier.scopusauthoridTung, Y=15819696200en_HK
dc.identifier.citeulike4698099-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats